PROX1 and thyroid gland carcinoma: Choi et al. found that the cell fate regulator PROX1 was inactivated in PTC at the mRNA expression, and that restoring PROX1 expression in thyroid cancer cells not only activated the Wnt/β-catenin pathway, but also regulated multiple other PTC-associated genes, indicating that PROX1 reactivation is a potential therapeutic strategy6.